Stellon A, Davies A, Webb A, Williams R
Postgrad Med J. 1985 Sep;61(719):791-6. doi: 10.1136/pgmj.61.719.791.
To determine whether microcrystalline hydroxyapatite compound (MCHC) could reduce bone loss or its consequences in patients with chronic active hepatitis (CAH) on corticosteroid therapy, a controlled trial was conducted in 36 such patients over a period of 2 years. Both skeletal symptoms (back pain) and fractures were uncommon during the trial period but both showed non-significant differences in favour of the MCHC group and biochemical investigations were suggestive of a reduction in parathyroid over-activity. Continued reduction in bone mineral content of the radius (photon absorptiometry) was halted in those receiving MCHC and iliac crest bone biopsy showed a non-significant increase in trabecular bone volume. The fall in iliac crest cortical plate thickness was significantly less (P less than 0.025) in the MCHC group and the results overall were consistent with a beneficial effect from MCHC in corticosteroid-induced osteoporosis.
为了确定微晶羟基磷灰石化合物（MCHC）能否减少接受皮质类固醇治疗的慢性活动性肝炎（CAH）患者的骨质流失或其后果，对36例此类患者进行了为期2年的对照试验。在试验期间，骨骼症状（背痛）和骨折均不常见，但两者均显示出有利于MCHC组的非显著差异，并且生化检查提示甲状旁腺过度活跃有所减轻。接受MCHC的患者桡骨骨矿物质含量（光子吸收法）的持续下降停止，髂嵴骨活检显示小梁骨体积有非显著增加。MCHC组髂嵴皮质板厚度的下降明显较少（P小于0.025），总体结果与MCHC对皮质类固醇诱导的骨质疏松症有有益作用一致。
